

Critical perspectives, commentaries and reviews

GENERAL

Heaney RP. How does bone support calcium homeostasis? *Bone*. 2003; 33:264-8.

Parfitt AM. Misconceptions (3): calcium leaves bone only by resorption and enters only by formation. *Bone*. 2003 33:259-63.

Dempster DW. The pathophysiology of bone loss. *Clinics in Geriatric Medicine*. 2003; 19):259-70,

EPIDEMIOLOGY

Wehren LE. The epidemiology of osteoporosis and fractures in geriatric medicine. *Clinics in Geriatric Medicine*. 2003;19:245-58

GENETIC

Dvornyk V, Recker RR, Deng HW. Gene expression studies of osteoporosis: implications for microarray research. *Osteoporos Int*. 2003;14:451-61

RISK FACTORS

Kerstetter JE. O'Brien KO. Insogna KL. Dietary protein, calcium metabolism, and skeletal homeostasis revisited. *American Journal of Clinical Nutrition*. 2003;78(3 Suppl):584S-592S, 2003 Sep.

SYSTEMIC FACTORS

Malabanan AO. Holick MF. Vitamin D and bone health in postmenopausal women. [Review] [30 refs] *Journal of Women's Health*. 2003;12:151-6

MEASUREMENT

Miller PD. Bone mass measurements. *Clinics in Geriatric Medicine*. 2003: 19:281-97

Link TM. Majumdar S. Osteoporosis imaging. *Radiologic Clinics of North America*. 2003; 41(4):813-39

Holick MF The parathyroid hormone D-lemma *J Clin Endocrinol Metab*. 2003;88:3499-500.

CORTICOSTEROIDS REVIEW

Loddenkemper K. Grauer A. Burmester GR. Buttgereit F. Calcium, vitamin D and etidronate for the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases. *Clinical & Experimental Rheumatology*. 2003; 2:19-26,

BIOMECHANICS

Currey JD. How well are bones designed to resist fracture? *J Bone Miner Res*. 2003 Apr;18(4):591-8.

ARCHITECTURE

Orwoll ES. Toward an expanded understanding of the role of the periosteum in skeletal health. *J Bone Miner Res*. 2003;18:949-54

TREATMENT

Rosen CJ, Wuster C Growth hormone rising: did we quit too quickly? *J Bone Miner Res*. 2003;18:406-9

S Migliaccio ,J J B Anderson Isoflavones and skeletal health: are these molecules ready for clinical application *Osteoporos Int* 2003;14:361-8

- Bauer DC. HMG CoA reductase inhibitors and the skeleton: a comprehensive review. *Osteoporos Int.* 2003; 14:273-82
- Levine RJ. Placebo controls in clinical trials of new therapies for osteoporosis. *J Bone Miner Res.* 2003 Jun;18(6):1154-9.
- Weijer C. The ethics of placebo-controlled trials. *J Bone Miner Res.* 2003;18:1150-3.
- Khosla S. Surrogates for fracture endpoints in clinical trials. *J Bone Miner Res.* 2003; 18:1146-9.
- Rosenblatt M. Is it ethical to conduct placebo-controlled clinical trials in the development of new agents for osteoporosis? An industry perspective. *J Bone Miner Res.* 2003 Jun;18:1142-5.
- Nishii Y. Rationale for active vitamin D and analogs in the treatment of osteoporosis. *Journal of Cellular Biochemistry.* 2003; 88:381-6.
- Elizabeth Barrett-Connor An Epidemiologist Looks at Hormones and Heart Disease in Women. *J Clin Endocrinol Metab* 2003;88 4031-4042
- Rubin MR. Bilezikian JP. The anabolic effects of parathyroid hormone therapy. *Clinics in Geriatric Medicine.* 2003; 19:415-32,
- Khosla S. Parathyroid hormone plus alendronate--a combination that does not add Up. *New England Journal of Medicine.* 2003; 349:1277-9.
- Reginster JY. Deroisy R. Jupsin I. Strontium ranelate: a new paradigm in the treatment of osteoporosis. *Drugs of Today.* 2003; 39:89-101
- Watts NB. Bisphosphonate treatment of osteoporosis. *Clinics in Geriatric Medicine.* 2003;19:395-414
- Cosman F. Selective estrogen-receptor modulators. *Clinics in Geriatric Medicine.* 2003; 19:371-9
- Cranney A. Wells GA. Hormone replacement therapy for postmenopausal osteoporosis. *Clinics in Geriatric Medicine.* 2003; 19:361-70
- Sinaki M. Nonpharmacologic interventions. Exercise, fall prevention, and role of physical medicine. *Clinics in Geriatric Medicine.* 2003;19(2):337-59
- Nieves JW. Calcium, vitamin D, and nutrition in elderly adults. *Clinics in Geriatric Medicine.* 2003; 19(2):321-35
- Schimmer RC. Bauss F. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. *Clinical Therapeutics.* 2003; 25:19-34
- Body JJ. Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis. *Expert Opinion on Pharmacotherapy.* 2003; 4:567-80
- McClung MR. The menopause and HRT. Prevention and management of osteoporosis. *Clinical & Experimental Rheumatology.* 2003; 21:103-6